Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
about
Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future PerspectivesThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyThe Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer DrugsArginine methyltransferases as novel therapeutic targets for breast cancerReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantEndocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersClinical significance of estrogen receptor β in breast and prostate cancer from biological aspectsA multi-targeted approach to suppress tumor-promoting inflammationStachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathwaysComparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Genistein Protects Genioglossus Myoblast Against Hypoxia-induced Injury through PI3K-Akt and ERK MAPK PathwaysMicroparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells.Animal models and therapeutic molecular targets of cancer: utility and limitations.Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activityThe role of epigenetics in personalized medicine: challenges and opportunities.Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencingMitochondrial maintenance failure in aging and role of sexual dimorphism.MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2CaCO₃/CaIP₆ composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth.The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells.Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell LineClinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cellsEndocrine resistance in breast cancer--An overview and update.Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferationMolecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Portraying breast cancers with long noncoding RNAs.Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells.Arctigenin functions as a selective agonist of estrogen receptor β to restrict mTORC1 activation and consequent Th17 differentiation.Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.mTOR function and therapeutic targeting in breast cancer.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.Estradiol activates chloride channels via estrogen receptor-α in the cell membranes of osteoblasts.Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in PTEN-deficient Lipoma Cells by Suppressing p70S6 Kinase Activity.Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance.DNA Repair in Despair-Vitamin D Is Not Fair.Dietary Intervention by Phytochemicals and Their Role in Modulating Coding and Non-Coding Genes in Cancer.Targeting the mTOR pathway in breast cancer.Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyCryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
P2860
Q26772042-0C46DE2B-CE84-4957-A2B6-84FF2D956F0EQ26799596-B69EB187-4C19-4016-8929-AA1AF6233E27Q26801532-9A8998AE-3D40-48CE-82CF-F7090C5B8A49Q26851594-FC92B116-90AF-48F2-B795-8C5B8C76A119Q28076777-C3F80163-C0D8-4D21-92DF-6E4F686F8E60Q28081872-6E2CD1E1-DC92-415B-B5E3-155AC3A912CAQ28087001-FAB0D3DB-489E-4055-967D-82342881D991Q28393278-A4D62AAC-4BBA-4FF5-8A8C-EAA00A03B424Q33623156-BA3D4D07-BB74-484E-91DC-B2E1B7F439D6Q33674656-CCA79D32-C7DD-44F3-B63F-4D81FCCEF409Q33895084-C18B9F6C-C86D-47F2-850B-9A481859C433Q34048932-9DED80D9-611A-4CC7-80A4-22AFC8CAB3AAQ34386828-60D92D2C-3385-471B-95DE-C38233AC262AQ34554594-820932DD-A1FF-4F0B-B2F0-C45BD6925581Q35043066-DA2FF71B-5EB1-4D2D-957B-3BE4FDA29645Q35142605-BAB3BE44-58AE-4703-9058-1D63B4686592Q35538600-89605D14-A2DE-4E77-89CB-149FDC0B6ADEQ35673311-934FD068-E927-4947-A835-C743F7C9E8D9Q35690245-8ADD06BA-0216-43A4-B1FF-EFB06C984CD7Q35819635-039B585C-5146-4FD6-A01D-9F95EE7B6186Q36022772-99EB7D10-49E2-4CD0-ADB1-A9B88DE9E949Q36279825-1944F896-1261-40FC-AE4D-1C263B4E814EQ36327268-9D0506D3-FAFB-4965-8FBF-73A9D5F45AEEQ36386322-AC8EBD16-3C3C-4B23-B252-36C470B2929AQ36710997-625FB23E-325E-4267-A3CC-4C83DD1C28DCQ36849266-234B2CE5-267C-4935-B33D-16E1E90AB01CQ37230214-582199D2-281B-4C15-8F36-E26D8719E0AAQ37687014-F60941A3-5907-48C1-AB82-B66DA7FB6551Q37708911-34861B42-6BF3-44DA-B0D1-BBF9485A4AA3Q37708928-C108246E-821A-4B13-B106-EFAFF905B81BQ37743486-7C311183-FB39-4A41-AA9B-DBFE60A55177Q38469746-D7469E1B-4A85-4CBC-9367-F522F18D8B55Q38704980-219B0591-288A-480D-8553-A36747861E46Q38788920-C18B5198-2ED3-420D-B172-4BF12C461824Q38838851-1487ACC9-57FE-4206-82C4-62D6D4494288Q38874859-2CCC46CF-2A40-41FC-918B-BFCC8E3B4E29Q39354574-9EA2AD6D-3A72-471D-BDBA-2BB624357F0AQ39390640-A5744F26-F01C-42F0-9BA1-955B0EBDB649Q41302136-4DC383C9-1F68-43C5-B956-C3DCF879F1C0Q41520280-7354586D-A5CC-4224-9333-F215FD110CCD
P2860
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
@en
type
label
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
@en
prefLabel
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
@en
P1476
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
@en
P2093
Eva Maria Ciruelos Gil
P304
P356
10.1016/J.CTRV.2014.03.004
P577
2014-03-26T00:00:00Z